# Airgain Inc: financial statements, quarterly

AIRG · Nasdaq · CIK 1272842 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/airg.md) · [Financials](/companies/airg/financials.md) · [Filings](/companies/airg/filings.md) · [Insiders](/companies/airg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/airg/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [13.7](/filings/0000950170-24-125669.md) | [10.1 d](/filings/0000950170-25-029234.md) | [14.2](/filings/0000950170-25-065872.md) | [15.2](/filings/0000950170-25-104171.md) | [16.1](/filings/0001193125-25-277931.md) | [15.1 d](/filings/0001193125-26-076752.md) | [12.0](/filings/0001193125-26-209133.md) | [13.6](/filings/0001193125-26-335336.md) | [14.0](/filings/0001193125-25-277931.md) | [12.1 d](/filings/0001193125-26-076752.md) | [11.5](/filings/0001193125-26-209133.md) | [13.7](/filings/0001193125-26-335336.md) |
| Cost of revenue | $m | [8.5](/filings/0000950170-24-125669.md) | [7.1 d](/filings/0000950170-25-029234.md) | [8.7](/filings/0000950170-25-065872.md) | [9.0](/filings/0000950170-25-104171.md) | [9.4](/filings/0001193125-25-277931.md) | [8.7 d](/filings/0001193125-26-076752.md) | [6.9](/filings/0001193125-26-209133.md) | [7.8](/filings/0001193125-26-335336.md) | [7.9](/filings/0001193125-25-277931.md) | [6.7 d](/filings/0001193125-26-076752.md) | [6.5](/filings/0001193125-26-209133.md) | [7.9](/filings/0001193125-26-335336.md) |
| Gross profit | $m | [5.2](/filings/0000950170-24-125669.md) | [2.9 d](/filings/0000950170-25-029234.md) | [5.6](/filings/0000950170-25-065872.md) | [6.1](/filings/0000950170-25-104171.md) | [6.7](/filings/0001193125-25-277931.md) | [6.4 d](/filings/0001193125-26-076752.md) | [5.2](/filings/0001193125-26-209133.md) | [5.8](/filings/0001193125-26-335336.md) | [6.1](/filings/0001193125-25-277931.md) | [5.4 d](/filings/0001193125-26-076752.md) | [5.0](/filings/0001193125-26-209133.md) | [5.8](/filings/0001193125-26-335336.md) |
| Research and development | $m | [2.3](/filings/0000950170-24-125669.md) | [3.2 d](/filings/0000950170-25-029234.md) | [3.1](/filings/0000950170-25-065872.md) | [3.1](/filings/0000950170-25-104171.md) | [2.9](/filings/0001193125-25-277931.md) | [2.8 d](/filings/0001193125-26-076752.md) | [2.5](/filings/0001193125-26-209133.md) | [2.6](/filings/0001193125-26-335336.md) | [2.1](/filings/0001193125-25-277931.md) | [2.4 d](/filings/0001193125-26-076752.md) | [2.2](/filings/0001193125-26-209133.md) | [2.9](/filings/0001193125-26-335336.md) |
| Operating income | $m | [(1.9)](/filings/0000950170-24-125669.md) | [(5.5) d](/filings/0000950170-25-029234.md) | [(2.6)](/filings/0000950170-25-065872.md) | [(2.5)](/filings/0000950170-25-104171.md) | [(1.8)](/filings/0001193125-25-277931.md) | [(2.0) d](/filings/0001193125-26-076752.md) | [(3.1)](/filings/0001193125-26-209133.md) | [(2.0)](/filings/0001193125-26-335336.md) | [(1.0)](/filings/0001193125-25-277931.md) | [(2.4) d](/filings/0001193125-26-076752.md) | [(2.1)](/filings/0001193125-26-209133.md) | [(1.7)](/filings/0001193125-26-335336.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0000950170-24-125669.md) | [0.0 d](/filings/0000950170-25-029234.md) | [(0.1)](/filings/0000950170-25-065872.md) | [0.0](/filings/0000950170-25-104171.md) | [(0.0)](/filings/0001193125-25-277931.md) | [(0.0) d](/filings/0001193125-26-076752.md) | [0.0](/filings/0001193125-26-209133.md) | [0.0](/filings/0001193125-26-335336.md) | [0.0](/filings/0001193125-25-277931.md) | [0.0 d](/filings/0001193125-26-076752.md) | [0.1](/filings/0001193125-26-209133.md) | [(0.0)](/filings/0001193125-26-335336.md) |
| Net income | $m | [(1.9)](/filings/0000950170-24-125669.md) | [(5.5) d](/filings/0000950170-25-029234.md) | [(2.5)](/filings/0001193125-25-277931.md) | [(2.5)](/filings/0001193125-25-277931.md) | [(1.8)](/filings/0001193125-25-277931.md) | [(2.0) d](/filings/0001193125-26-076752.md) | [(1.5)](/filings/0001193125-26-335336.md) | [(1.5)](/filings/0001193125-26-335336.md) | [(1.0)](/filings/0001193125-25-277931.md) | [(2.4) d](/filings/0001193125-26-076752.md) | [(1.9)](/filings/0001193125-26-335336.md) | [(1.7)](/filings/0001193125-26-335336.md) |
| Diluted EPS | $ per share | [(0.18)](/filings/0000950170-24-125669.md) | not reported | [(0.23)](/filings/0000950170-25-065872.md) | [(0.23)](/filings/0000950170-25-104171.md) | [(0.16)](/filings/0001193125-25-277931.md) | not reported | [(0.13)](/filings/0001193125-26-209133.md) | [(0.12)](/filings/0001193125-26-335336.md) | [(0.08)](/filings/0001193125-25-277931.md) | not reported | [(0.15)](/filings/0001193125-26-209133.md) | [(0.13)](/filings/0001193125-26-335336.md) |
| Basic EPS | $ per share | [(0.18)](/filings/0000950170-24-125669.md) | not reported | [(0.23)](/filings/0000950170-25-065872.md) | [(0.23)](/filings/0000950170-25-104171.md) | [(0.16)](/filings/0001193125-25-277931.md) | not reported | [(0.13)](/filings/0001193125-26-209133.md) | [(0.12)](/filings/0001193125-26-335336.md) | [(0.08)](/filings/0001193125-25-277931.md) | not reported | [(0.15)](/filings/0001193125-26-209133.md) | [(0.13)](/filings/0001193125-26-335336.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [10.0](/filings/0000950170-24-125669.md) | [7.9](/filings/0000950170-25-029234.md) | [7.2](/filings/0000950170-25-065872.md) | [8.4](/filings/0000950170-25-104171.md) | [7.3](/filings/0001193125-25-277931.md) | [8.5](/filings/0001193125-26-076752.md) | [7.4](/filings/0001193125-26-209133.md) | [7.7](/filings/0001193125-26-335336.md) | [7.1](/filings/0001193125-25-277931.md) | [7.4](/filings/0001193125-26-335336.md) | [7.1](/filings/0001193125-26-209133.md) | [7.6](/filings/0001193125-26-335336.md) |
| Current assets | $m | [22.3](/filings/0000950170-23-062233.md) | [19.1](/filings/0000950170-25-029234.md) | [20.8](/filings/0000950170-24-055887.md) | [21.3](/filings/0000950170-24-092012.md) | [23.3](/filings/0000950170-24-125669.md) | [25.8](/filings/0001193125-26-076752.md) | [24.0](/filings/0000950170-25-065872.md) | [24.6](/filings/0000950170-25-104171.md) | [25.2](/filings/0001193125-25-277931.md) | [25.8](/filings/0001193125-26-335336.md) | [23.8](/filings/0001193125-26-209133.md) | [27.7](/filings/0001193125-26-335336.md) |
| Total assets | $m | [46.3](/filings/0000950170-23-062233.md) | [42.2](/filings/0000950170-25-029234.md) | [42.8](/filings/0000950170-24-055887.md) | [42.4](/filings/0000950170-24-092012.md) | [43.3](/filings/0000950170-24-125669.md) | [48.4](/filings/0001193125-26-076752.md) | [46.1](/filings/0000950170-25-065872.md) | [45.5](/filings/0000950170-25-104171.md) | [45.5](/filings/0001193125-25-277931.md) | [45.3](/filings/0001193125-26-335336.md) | [43.4](/filings/0001193125-26-209133.md) | [46.8](/filings/0001193125-26-335336.md) |
| Current liabilities | $m | [9.5](/filings/0000950170-23-062233.md) | [10.0](/filings/0000950170-25-029234.md) | [11.7](/filings/0000950170-24-055887.md) | [10.3](/filings/0000950170-24-092012.md) | [12.1](/filings/0000950170-24-125669.md) | [13.5](/filings/0001193125-26-076752.md) | [11.4](/filings/0000950170-25-065872.md) | [11.8](/filings/0000950170-25-104171.md) | [11.8](/filings/0001193125-25-277931.md) | [13.0](/filings/0001193125-26-335336.md) | [11.5](/filings/0001193125-26-209133.md) | [13.8](/filings/0001193125-26-335336.md) |
| Total liabilities | $m | [10.5](/filings/0000950170-23-062233.md) | [10.8](/filings/0000950170-25-029234.md) | [12.3](/filings/0000950170-24-055887.md) | [10.8](/filings/0000950170-24-092012.md) | [12.4](/filings/0000950170-24-125669.md) | [17.5](/filings/0001193125-26-076752.md) | [15.8](/filings/0000950170-25-065872.md) | [15.7](/filings/0000950170-25-104171.md) | [15.8](/filings/0001193125-25-277931.md) | [17.0](/filings/0001193125-26-335336.md) | [15.4](/filings/0001193125-26-209133.md) | [17.5](/filings/0001193125-26-335336.md) |
| Shareholders' equity | $m | [35.8](/filings/0000950170-24-125669.md) | [31.4](/filings/0001193125-26-076752.md) | [30.5](/filings/0001193125-25-277931.md) | [31.6](/filings/0001193125-25-277931.md) | [30.8](/filings/0001193125-25-277931.md) | [31.0](/filings/0001193125-26-335336.md) | [30.3](/filings/0001193125-26-335336.md) | [29.8](/filings/0001193125-26-335336.md) | [29.7](/filings/0001193125-25-277931.md) | [28.3](/filings/0001193125-26-335336.md) | [28.0](/filings/0001193125-26-335336.md) | [29.3](/filings/0001193125-26-335336.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [640 d](/filings/0000950170-24-125669.md) | [(1,937) d](/filings/0000950170-25-029234.md) | [(1,119)](/filings/0000950170-25-065872.md) | [(1,203) d](/filings/0000950170-25-104171.md) | [(1,179) d](/filings/0001193125-25-277931.md) | [(26.0) d](/filings/0001193125-26-076752.md) | [(1,025)](/filings/0001193125-26-209133.md) | [129 d](/filings/0001193125-26-335336.md) | [(411) d](/filings/0001193125-25-277931.md) | [194 d](/filings/0001193125-26-076752.md) | [(759)](/filings/0001193125-26-209133.md) | [(1,791) d](/filings/0001193125-26-335336.md) |
| Capital expenditure | $k | [68.0 d](/filings/0000950170-24-125669.md) | [174 d](/filings/0000950170-25-029234.md) | [60.0](/filings/0000950170-25-065872.md) | [90.0 d](/filings/0000950170-25-104171.md) | [27.0 d](/filings/0001193125-25-277931.md) | [1.0 d](/filings/0001193125-26-076752.md) | [42.0](/filings/0001193125-26-209133.md) | [16.0 d](/filings/0001193125-26-335336.md) | [7.0 d](/filings/0001193125-25-277931.md) | [101 d](/filings/0001193125-26-076752.md) | [55.0](/filings/0001193125-26-209133.md) | [35.0 d](/filings/0001193125-26-335336.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [10.2](/filings/0000950170-23-062233.md) | [10.3](/filings/0000950170-24-055887.md) | [10.4](/filings/0000950170-24-092012.md) | [10.4](/filings/0000950170-24-125669.md) | [10.5](/filings/0000950170-25-065872.md) | [10.9](/filings/0000950170-25-104171.md) | [11.3](/filings/0001193125-25-277931.md) | [11.6](/filings/0001193125-26-209133.md) | [11.8](/filings/0001193125-26-335336.md) | [11.8](/filings/0001193125-25-277931.md) | [12.3](/filings/0001193125-26-209133.md) | [12.8](/filings/0001193125-26-335336.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 13,100,234 at 2026-07-29, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335336.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.